<?xml version='1.0' encoding='utf-8'?>
<document id="21415249"><sentence text="Quantitative time-lapse imaging-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug resistance-associated protein 2, in sandwich-cultured rat hepatocytes." /><sentence text="There is increasing interest in developing efficient screening platforms to predict drug-induced liver injury" /><sentence text=" Therefore, we explored a microscope-based analysis to quantitatively evaluate interaction of drugs with multidrug resistance-associated protein 2 (MRP2), essential for hepatic excretion of drugs in sandwich-cultured rat hepatocytes (SCRHs), using 5 (and 6)-carboxy-2',7'-dichlorofluorescein (CDF) diacetate, which is intracellularly hydrolyzed to the fluorescent substrate CDF"><entity charOffset="298-307" id="DDI-PubMed.21415249.s3.e0" text="diacetate" /></sentence><sentence text=" Drug-MRP2 interactions were evaluated by measuring the fluorescence change in bile canaliculi in SCRHs in the presence or absence of MRP2 inhibitors using quantitative time-lapse imaging (QTLI) analysis" /><sentence text=" Fluorescence was negligible in SCHs from rat (r) Mrp2-deficient Eisai hyperbilirubinemic rat, suggesting that Mrp2 is primarily responsible for CDF accumulation" /><sentence text=" According to QTLI, rifampicin, cyclosporine, and 3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid (MK-571) attenuated CDF accumulation in a concentration-dependent manner, with IC₅₀ values (IC₅₀, QTLI)) of 3"><entity charOffset="14-18" id="DDI-PubMed.21415249.s6.e0" text="QTLI" /><entity charOffset="20-30" id="DDI-PubMed.21415249.s6.e1" text="rifampicin" /><entity charOffset="32-44" id="DDI-PubMed.21415249.s6.e2" text="cyclosporine" /><entity charOffset="50-160" id="DDI-PubMed.21415249.s6.e3" text="3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid" /><entity charOffset="259-368" id="DDI-PubMed.21415249.s6.e4" text="QTLI" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e0" e2="DDI-PubMed.21415249.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e0" e2="DDI-PubMed.21415249.s6.e1" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e0" e2="DDI-PubMed.21415249.s6.e2" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e0" e2="DDI-PubMed.21415249.s6.e3" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e0" e2="DDI-PubMed.21415249.s6.e4" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e1" e2="DDI-PubMed.21415249.s6.e1" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e1" e2="DDI-PubMed.21415249.s6.e2" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e1" e2="DDI-PubMed.21415249.s6.e3" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e1" e2="DDI-PubMed.21415249.s6.e4" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e2" e2="DDI-PubMed.21415249.s6.e2" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e2" e2="DDI-PubMed.21415249.s6.e3" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e2" e2="DDI-PubMed.21415249.s6.e4" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e3" e2="DDI-PubMed.21415249.s6.e3" /><pair ddi="false" e1="DDI-PubMed.21415249.s6.e3" e2="DDI-PubMed.21415249.s6.e4" /></sentence><sentence text="02, 1" /><sentence text="63, and 2" /><sentence text="87 μM, respectively" /><sentence text=" The ratios of IC₅₀ values obtained from the biliary excretion index over the IC(₅₀, QTLI) were 1"><entity charOffset="85-88" id="DDI-PubMed.21415249.s10.e0" text="QTLI" /></sentence><sentence text="34, 1" /><sentence text="94, and 1" /><sentence text="94, but ratios over IC₅₀ values in CDF uptake by Mrp2-expressing membrane vesicles varied more: 6" /><sentence text="69, 3" /><sentence text="07, and 2" /><sentence text="43 for rifampicin, cyclosporine, and MK-571, respectively"><entity charOffset="7-17" id="DDI-PubMed.21415249.s16.e0" text="rifampicin" /><entity charOffset="19-31" id="DDI-PubMed.21415249.s16.e1" text="cyclosporine" /><entity charOffset="37-43" id="DDI-PubMed.21415249.s16.e2" text="MK-571" /><pair ddi="false" e1="DDI-PubMed.21415249.s16.e0" e2="DDI-PubMed.21415249.s16.e0" /><pair ddi="false" e1="DDI-PubMed.21415249.s16.e0" e2="DDI-PubMed.21415249.s16.e1" /><pair ddi="false" e1="DDI-PubMed.21415249.s16.e0" e2="DDI-PubMed.21415249.s16.e2" /><pair ddi="false" e1="DDI-PubMed.21415249.s16.e1" e2="DDI-PubMed.21415249.s16.e1" /><pair ddi="false" e1="DDI-PubMed.21415249.s16.e1" e2="DDI-PubMed.21415249.s16.e2" /></sentence><sentence text=" When the IC(₅₀, QTLI) of rifampicin was corrected for the hepatocyte/medium distribution ratio, the relative ratio of IC(₅₀, VES)/IC(₅₀, QTLI) was reduced to 2"><entity charOffset="26-36" id="DDI-PubMed.21415249.s17.e0" text="rifampicin" /><entity charOffset="17-26" id="DDI-PubMed.21415249.s17.e1" text="QTLI" /><entity charOffset="138-147" id="DDI-PubMed.21415249.s17.e2" text="QTLI" /><pair ddi="false" e1="DDI-PubMed.21415249.s17.e1" e2="DDI-PubMed.21415249.s17.e1" /><pair ddi="false" e1="DDI-PubMed.21415249.s17.e1" e2="DDI-PubMed.21415249.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21415249.s17.e1" e2="DDI-PubMed.21415249.s17.e2" /><pair ddi="false" e1="DDI-PubMed.21415249.s17.e0" e2="DDI-PubMed.21415249.s17.e0" /><pair ddi="false" e1="DDI-PubMed.21415249.s17.e0" e2="DDI-PubMed.21415249.s17.e2" /></sentence><sentence text="25 from 6" /><sentence text="69 (20" /><sentence text="2/3" /><sentence text="02) and was close to the ratio for MK-571 (2" /><sentence text="43, 6" /><sentence text="96/2" /><sentence text="87), which is thought to cross the plasma membrane by passive diffusion" /><sentence text=" Our results indicate that QTLI is a suitable method to evaluate drug-MRP2 interaction at the bile canalicular membrane, when the hepatocyte/medium distribution ratio in SCRHs is taken into account"><entity charOffset="27-30" id="DDI-PubMed.21415249.s25.e0" text="QTLI" /></sentence><sentence text="" /></document>